Netakimab

DB18870InvestigationalProtein Based Therapies

Netakimab is under investigation in clinical trial NCT03447704 (International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis).

Mechanism: Pharmacologically active on Interleukin-17A
Curator reviewed
Also known as: Immunoglobulin g1, anti-(human interleukin 17) (human-lama glama monoclonal heavy chain), disulfide with human monoclonal light chain, dimer
Code names: BCD-085

Resolves to

Compound

UNIID3IAG45DAKCAS1796570-08-5

Clinical / RWD

ATCL04AC20

Targets

Q16552IL17A

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 12 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Netakimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account